Immunex Corporation

Jul 03, 02
09:00 ET	Second Phase 3 Pivotal Study of ENBREL(R) (etanercept) Initiated in Psoriasis
Jun 14, 02
08:00 ET	New Data Presented on ENBREL(R) (etanercept), Only Fully-Human TNF Soluble Receptor, Demonstrates Sustained Efficacy and Tolerability Up to 5 Years
08:00 ET	Treatment with ENBREL(R) (etanercept) Shows Improvements in Patient Functionality (HAQ Scores) for Both Newly Diagnosed RA Patients and Those With Established Disease
Jun 10, 02
15:04 ET	Immunex Participates in Investor Conference in June
May 16, 02
16:55 ET	Immunex Shareholders Approve Proposed Merger With Amgen Inc.
May 03, 02
09:00 ET	Immunex to Sell LEUKINE(R) (Sargramostim) to Schering AG Germany
00:01 ET	Immunex to Sell LEUKINE(R) (Sargramostim) to Schering AG Germany
Apr 29, 02
18:24 ET	Immunex Announces Settlement of Certain Litigations Relating To Merger With Amgen Inc.
Apr 22, 02
16:31 ET	Immunex Announces First Quarter 2002 Results
Apr 15, 02
09:00 ET	Immunex Secures Additional Manufacturing Capacity for ENBREL(R) (etanercept) At Genentech, Inc.
Apr 09, 02
17:00 ET	Immunex Announces Release Date of First Quarter Earnings
Mar 07, 02
19:02 ET	Immunex Corporation Released the Following Statement in Response to a Lawsuit Filed Today By Zymogenetics, Inc.
Feb 07, 02
11:56 ET	Immunex Schedules Investor Conference for February
Feb 06, 02
17:00 ET	Genesis Research and Immunex Corporation Sign New Collaboration Agreement
Jan 23, 02
16:30 ET	Immunex Posts Record Sales and Net Income for 2001
Jan 16, 02
09:01 ET	ENBREL(R) (etanercept) Is First Therapy Approved for Treatment of Psoriatic Arthritis
Jan 02, 02
17:31 ET	Immunex Announces Release Date of Fourth Quarter Earnings and Investor Conferences for January
Nov 28, 01
09:02 ET	Immunex Breaks New Ground in Biotech Manufacturing With Start Of BioNext Project(TM) in Rhode Island
Nov 11, 01
20:30 ET	New Phase 2 Study Shows Ankylosing Spondylitis Patients Respond to ENBREL(R) (etanercept)
20:30 ET	Phase 3 Psoriatic Arthritis Data for ENBREL(R) (etanercept) Announced at a National Scientific Meeting
Nov 07, 01
09:02 ET	Immunex Moves to Create One of the World's Most Advanced Cell Culture Manufacturing Centers
Nov 06, 01
09:02 ET	Immunex Issued Three Patents on Innovative Cell Expression System to Advance Drug Development and Manufacturing
Nov 01, 01
12:56 ET	Immunex Schedules Investor Conferences for November
Oct 17, 01
16:31 ET	Immunex Reports Third Quarter 2001 Results
Oct 16, 01
16:30 ET	New Appointments to Immunex Discovery Research Team
Oct 03, 01
16:15 ET	Immunex Announces Date of Third Quarter Earnings Release and Investor Conferences for October
Sep 26, 01
16:15 ET	Immunex Corporation Appoints Laura Hamill to Vice President, Marketing For ENBREL(R) (etanercept)
Sep 17, 01
12:05 ET	FDA Assigns 'Priority Review' Status to ENBREL(R) (etanercept) sBLA For Treatment of Psoriatic Arthritis
Sep 10, 01
09:00 ET	Immunex Expands Commercial Operation With New Sales Team
Aug 30, 01
13:00 ET	Immunex Schedules Investor Conference for September
Aug 20, 01
16:30 ET	Immunex Announces Positive Results With ENBREL(R) (etanercept) in Psoriasis
Aug 14, 01
16:30 ET	Immunex Announces Next Step to Boost ENBREL(R) (etanercept) Production
Aug 13, 01
09:01 ET	Immunex, Wyeth-Ayerst Initiate RADIUS, One of the Largest Longitudinal Studies Of Rheumatoid Arthritis Patients
Jul 31, 01
13:00 ET	Immunex Schedules Investor Conferences for August
Jul 26, 01
16:30 ET	Empowering People with Rheumatoid Arthritis (RA) Through Awareness and Education
Jul 18, 01
16:31 ET	Immunex Reports Second Quarter 2001 Financial Results
Jul 16, 01
16:30 ET	ENBREL(R) (etanercept) Becomes First Product to Be Reviewed by FDA For Treatment of Psoriatic Arthritis
Jul 13, 01
09:05 ET	The 'Immunex All Stars' Celebrate 20 Years of Breakthrough Science
09:00 ET	Immunex Moves Interleukin-1 Receptor Type II Into Human Clinical Testing
Jul 02, 01
13:00 ET	Immunex Announces Date of Second Quarter 2001 Earnings Release And Conference Call
Jun 15, 01
09:00 ET	ENBREL(R) (etanercept) Monotherapy Treatment Results Show Sustained Efficacy, Ongoing Tolerability Through 4 Years of Study
Jun 04, 01
16:30 ET	Immunex Corporation Promotes Philip Laub to Vice President of Human Resources
Jun 01, 01
11:00 ET	Immunex Schedules Investor Conferences for June
May 22, 01
16:31 ET	Immunex Promotes Carl March, Ph.D. to Senior Vice President
May 21, 01
09:00 ET	Cambridge Antibody Technology and Immunex Corporation Enter Into New Alliance For Human Monoclonal Antibody Co-Development
May 18, 01
09:00 ET	New Study Suggests NOVANTRONE(R) (Mitoxantrone for Injection Concentrate) May Help Prostate Cancer Patients Naive to Hormone Therapy
May 14, 01
16:15 ET	Tolerability Demonstrated by ABX-EGF as Monotherapy in Advanced Cancers
May 10, 01
07:32 ET	Double-Drug Therapy May Benefit Some Multiple Sclerosis Patients
May 01, 01
17:00 ET	Immunex Schedules Investor Conferences for May
Apr 18, 01
16:41 ET	Immunex Announces First Quarter 2001 Results
09:00 ET	Abgenix and Immunex to Initiate Phase 2 Clinical Trial Of ABX-EGF in Kidney Cancer
Apr 11, 01
16:15 ET	ENBREL Enrollment Program Expands: ENBREL(R) (etanercept) Now Available to New Patients Enrolled in Queue System As of March 31, 2001
Apr 02, 01
16:30 ET	Immunex Announces Date of First Quarter 2001 Earnings Release and Conference Call
Mar 22, 01
16:22 ET	CHF Studies of ENBREL(R) (etanercept) Will Conclude Early, Monitoring Board Advises Study Not Likely to Meet Efficacy Endpoints
16:21 ET	Study Results Positive for Phase III Study of ENBREL(R) (etanercept) In Psoriatic Arthritis
16:20 ET	Data from Two of Three Studies With NUVANCE(TM) (soluble IL-4 receptor) Analyzed
Mar 12, 01
16:30 ET	Immunex Elects Former Microsoft COO Robert J. Herbold to Serve on Company's Board of Directors
Mar 01, 01
11:00 ET	Immunex Schedules Investor Conferences for March
Feb 28, 01
11:00 ET	Immunex Corporation Solidifies Plan for Additional Long-Term Growth With Key Personnel
Feb 06, 01
13:00 ET	Immunex Schedules Investor Conferences for February
Jan 25, 01
09:30 ET	Immunex Announces Construction Plans for Helix Project
Jan 24, 01
16:30 ET	Immunex Reports Financial Results for 2000
Jan 23, 01
11:30 ET	Immunex Breaks New Ground With Helix Project: State-of-the-Art Research And Technology Center
Jan 17, 01
11:31 ET	Immunex Corporation Promotes Daniel Burge, M.D. to Vice President of Clinical Development
Jan 10, 01
16:36 ET	Immunex Schedules Fourth Quarter 2000 Financial Results for January 24, 2001
Jan 09, 01
16:00 ET	Immunex Chief Executive Officer to Present at the Chase H&Q 19th Annual Healthcare Conference
Jan 03, 01
17:12 ET	First Phase of ENBREL(R) (etanercept) Enrollment Program Completed Successfully
Dec 18, 00
13:00 ET	Immunex Corporation Nationally Recognized as a 'Great Place to Work'
Dec 08, 00
08:01 ET	Health Canada Approves ENBREL(R) (etanercept) for the Treatment of Moderately To Severely Active Rheumatoid Arthritis
Nov 29, 00
18:50 ET	ENBREL(R) (etanercept) Shown to Delay Structural Damage in Patients With Moderately to Severely Active Rheumatoid Arthritis
Nov 28, 00
07:31 ET	Abgenix and Immunex to Develop Novel Anti-Cancer Antibodies
Nov 14, 00
09:00 ET	Immunex Announces Exercise of Over-Allotment Option Completing Largest Biotech Offering Ever
Nov 10, 00
13:57 ET	TNF Inhibition a Focus at the American Heart Association 73rd Scientific Sessions
09:00 ET	Immunex Corporation Announces Pricing of Equity Offering
Nov 02, 00
10:00 ET	American Home Products Corporation Converts $450 Million Convertible Subordinated Note From Immunex Corporation
Oct 31, 00
08:05 ET	Immunex Corporation Contributes $1 Million to Support the ACR Pediatric Rheumatology Visiting Professorship Program
Oct 30, 00
13:42 ET	First Two-Year Results of ENBREL(R) (etanercept) as First-Line Treatment for Moderately to Severely Active Rheumatoid Arthritis Presented at The American College of Rheumatology
Oct 29, 00
13:28 ET	ENBREL(R) (etanercept) Long-Term Clinical Trial Data Presented At The American College of Rheumatology Annual Meeting
Oct 20, 00
09:00 ET	Three Franchise Leaders Tapped for Promotions as Immunex Strengthens Commercial Operations Structure
Oct 18, 00
16:30 ET	Immunex Corporation Commences Equity Offering of 60 Million Shares Under Its Shelf Registration
16:30 ET	Immunex Reports Third Quarter 2000 Results
Oct 13, 00
11:50 ET	FDA Approves NOVANTRONE(R) for Worsening Forms of Multiple Sclerosis
Sep 19, 00
12:00 ET	Kimberly Ives to Serve as Immunex Vice President, Finance
Sep 13, 00
12:00 ET	Leslie Garrison, M.D., to Lead Immunex Clinical Development
Aug 09, 00
16:15 ET	Immunex Files Shelf Registration
Jul 26, 00
18:30 ET	Antibody Therapy Collaboration Announced By Abgenix, Inc. and Immunex Corporation
Jul 19, 00
16:31 ET	Immunex Reports Second Quarter 2000 Results
Jul 05, 00
06:00 ET	Immunex Licenses Prostate Cancer Antigens From UroCor for Research Against Prostate Cancer
Jun 28, 00
16:00 ET	Immunex Promotes Barry G. Pea to Senior Vice President and General Counsel; Scott Hallquist to Focus on Company's Alliance Strategy
Jun 27, 00
09:02 ET	Celera Genomics to Provide Database Subscription to Immunex Corporation
Jun 23, 00
09:00 ET	ENBREL(R) (etanercept) U.S. and European Long-Term Clinical Trial Data Presented at the Annual Meeting of the European League Against Rheumatism
Jun 20, 00
12:52 ET	New ENBREL(R) (etanercept) Marketing Vice President, Barry Labinger, Named by Immunex
Jun 08, 00
11:00 ET	Thomas O. Daniel, M.D., Appointed to Lead New Vascular Biology Research and Development Initiatives at Immunex
May 25, 00
16:00 ET	NUVANCE(TM) (Soluble IL-4 Receptor) Development Program to Progress Based On Results of Phase II Clinical Trial in Patients with Asthma
May 24, 00
11:00 ET	Oncologyknowledge.com Launched at ASCO Meeting in New Orleans
May 01, 00
17:09 ET	Immunex and Genentech Moving Forward With Preclinical Development Program Of TRAIL/Apo2L
Apr 18, 00
16:31 ET	Immunex Reports First Quarter 2000 Results
Apr 11, 00
15:07 ET	Use of ENBREL(R) (etanercept) to Delay Radiographic Progression of Joint Damage in Patients With Early Rheumatoid Arthritis Unanimously Recommended By FDA Arthritis Advisory Committee
Mar 15, 00
14:15 ET	ENBREL(R) (etanercept) Follow-Up Study in Chronic Heart Failure Presented At American College of Cardiology Meeting
Mar 02, 00
14:34 ET	NOVANTRONE(R) One Step Closer to FDA Approval to Treat Multiple Forms Of Multiple Sclerosis
Feb 22, 00
12:00 ET	Senior Pharmaceutical Executive, Mark Booth, to Lead Immunex Commercial Team for ENBREL
Feb 17, 00
16:14 ET	Immunex Announces 3-for-1 Common Stock Split
Feb 09, 00
10:00 ET	Immunex Joins Forces With University of Washington's New Academic-Private 'Cell Systems Initiative' Collaboration
Feb 03, 00
10:00 ET	New General Manager, Craig Parker, to Lead the Immunex Specialty Therapeutics Business
Jan 28, 00
19:55 ET	FDA Advisory Committee Recommends Approval of NOVANTRONE(R) For Treatment Of Worsening Multiple Sclerosis
Jan 25, 00
09:01 ET	Immunex Reports Financial Results for 1999
Dec 06, 99
09:03 ET	FDA Advisory Committee to Review NOVANTRONE(R) for Potential Use in Multiple Sclerosis
Nov 17, 99
10:30 ET	ENBREL(R) (etanercept) Long-Term Clinical Trial Data Presented at the American College of Rheumatology Meeting
Nov 03, 99
12:00 ET	Dave Mann is Chief Financial Officer for Immunex Corporation
Oct 18, 99
09:01 ET	Immunex Reports Third Quarter 1999 Results
Oct 12, 99
09:00 ET	Results of NUVANCE(TM) Phase I/II Asthma Trial Presented at European Respiratory Society Meeting
Oct 11, 99
17:56 ET	Peggy Phillips is New Chief Operating Officer for Immunex Corporation
Sep 16, 99
11:00 ET	Immunex Launches Multiple Sclerosis Educational Web Site
Jul 27, 99
16:02 ET	Immunex Announces 2-for-1 Common Stock Split
Jul 20, 99
09:01 ET	Immunex Reports Second Quarter 1999 Results
Jul 19, 99
09:02 ET	NOVANTRONE(R) Application for Multiple Sclerosis Granted Priority Review By FDA
Jun 03, 99
15:00 ET	Immunex Donation Is First for New Genetics Exhibit at Pacific Science Center
Jun 02, 99
10:45 ET	Immunex Will File Supplemental NDA for NOVANTRONE(R)
Jun 01, 99
08:30 ET	Immunex Corporation and Genentech, Inc. Join Forces to Develop TRAIL/Apo2L in Cancer
May 28, 99
08:00 ET	ENBREL(R) (etanercept) Receives FDA Approval for Treatment of Juvenile Rheumatoid Arthritis
May 20, 99
16:00 ET	Immunex Corporation Issues $450 Million Convertible Note to American Home Products Corporation
May 14, 99
09:00 ET	Immunex Advances CD40 Ligand to Phase II Clinical Trial in People With Metastatic Kidney Cancer
May 10, 99
16:14 ET	Positive Results of Pivotal Phase III Trial With ENBREL(R) in Patients With Early, Active Rheumatoid Arthritis
Apr 28, 99
19:30 ET	Immunex Chief Financial Officer, Douglas Southern, Retires
Apr 21, 99
14:13 ET	New Three-Year Follow-Up Data of NOVANTRONE(R) in Multiple Sclerosis Presented At Key Neurology Meeting
Apr 20, 99
09:01 ET	Immunex Reports First Quarter 1999 Results
Apr 06, 99
15:33 ET	ENBREL(R) (etanercept) Patient and Physician Support Web Site Launched
Mar 15, 99
17:00 ET	Immunex Issues Statement Regarding 1998 Tax Provision
Mar 08, 99
09:00 ET	Immunex and Wyeth-Ayerst Laboratories Advance ENBREL(R) Into Phase II/III Clinical Trial for Chronic Heart Failure
Mar 01, 99
09:02 ET	Immunex Advances NUVANCE(TM) to Phase II Clinical Trials in People With Asthma
Feb 23, 99
16:00 ET	Immunex Announces 2-for-1 Common Stock Split
Feb 03, 99
09:00 ET	Immunex Reports Financial Results for 1998
Feb 01, 99
17:00 ET	Immunex's TRAIL Molecule Shows Potential as Anti-Tumor Agent
Dec 08, 98
09:00 ET	Immunex Awarded Method of Use Patent on Mobist(TM)
Dec 07, 98
09:00 ET	Combining Immune System Molecules Mobist(TM) and CD40 Ligand Increases Rejection of Tumors in Mice
Nov 25, 98
09:00 ET	ENBREL(TM) for Juvenile Rheumatoid Arthritis Indication Filed With the Food and Drug Administration
Nov 12, 98
13:45 ET	New Two Year Data with ENBREL(TM) in Rheumatoid Arthritis Presented At The American College of Rheumatology Meeting
Nov 05, 98
09:01 ET	Immunex Awarded Patent on TACE Molecule
Oct 22, 98
09:00 ET	Leslie Garrison Promoted to Immunex Vice President, Clinical Development
Oct 14, 98
09:00 ET	Immunex Reports Third Quarter 1998 Results
Sep 16, 98
17:41 ET	Immunex Drug ENBREL(TM) Recommended for Approval By FDA Advisory Committee For Treatment of Rheumatoid Arthritis
Sep 14, 98
12:00 ET	Barry Pea Promoted to Immunex Vice President and Deputy General Counsel
Sep 10, 98
09:00 ET	First Novantrone Phase III Results in Multiple Sclerosis
Sep 03, 98
09:00 ET	Study Results Positive for New Approach to Treat Juvenile Rheumatoid Arthritis
Aug 20, 98
20:13 ET	FDA Advisory Committee Will Review Enbrel(TM) for Potential Use in Active Rheumatoid Arthritis
Aug 13, 98
09:00 ET	FDA Confirms First Filed Paclitaxel Injection Application
Aug 06, 98
12:00 ET	Immunex Licenses G-CSF Receptor Patent Rights to SmithKline Beecham
Aug 04, 98
20:13 ET	FDA Advisory Committee Will Review Enbrel(TM) for Potential Use in Active Rheumatoid Arthritis